Bhava is a Bevacizumab biosimilar and it will be marketed in strengths of 100 mg/4ml and 400 mg/16ml. Zydus Life said in a statement that Bhava is used for the treatment used for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic breast cancer, glioblastoma, advanced and/or metastatic renal cell carcinoma and ovarian cancer.
As per a WHO 2020 report which stated that of all the cancer cases reported in Mexico, breast, prostate, colorectal and thyroid were among the common ones. In 2015, Zydus had developed and launched the Bevacizumab biosimilar in India under the brand name Bryxta and it was developed at the Zydus Research Centre. The company said ever since the introduction of drug in the market an estimated 50,000 patients have been treated with the therapy.
Zydus Life’s Managing Director Sharvil Patel said the company has been developing a pipeline of biosimilars, specifically in oncology, to bring in greater access and affordability to patients battling critical ailments. “Precision diagnostics and access to affordable therapies are empowering millions of patients in their fight against cancer in India. With Bhava, we begin a new journey of supporting patients with need-based therapies in Latin America,” Patel added with Bhava we begin a new journey of supporting patients in Latin America with need-based therapies.
Last week, Zydus Life received two observations from the USFDA for its transdermal manufacturing site located at the SEZ in Ahmedabad. The US regulator had conducted the inspection at the site from July 15 to July 19 2024 and closed it with two observations. The company said it was confident of resolving all the issues raised by the USFDA within the stipulated timeline and is committed to resolving the same at the earliest.
Read More: Click Here
